1-(Diphenylmethyl)-4-[(2E)-3-phenyl-2-propen-1-yl]piperazine

368.51392

368.51

240-749-2

3DI2E1X18L

290687

DTXSID3022821

N07CA02|N - Nervous system

6.5

5.77

1.1±0.1 g/cm3

509.2±38.0 °C at 760 mmHg

229.8±14.6 °C

1.626

0.00 M

1.74E-10mmHg at 25°C

206.2 Ų [M+H]+ [CCS Type: TW, Method: Major Mix IMS/Tof Calibration Kit (Waters)]

P201, P202, P261, P264, P270, P271, P272, P273, P280, P281, P301+P312, P302+P352, P304+P312, P304+P340, P305+P351+P338, P308+P313, P312, P321, P330, P332+P313, P333+P313, P337+P313, P362, P363, P391, P403+P233, P405, P501

H302

H413 (100%): May cause long lasting harmful effects to aquatic life [Hazardous to the aquatic environment, long-term hazard]|P273, and P501|The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)|Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)

Cinnarizine has known human metabolites that include 1-Benzhydrylpiperazine, 1-Cinnamylpiperazine, 4-{3-[4-(diphenylmethyl)piperazin-1-yl]prop-1-en-1-yl}phenol, 4-{phenyl[4-(3-phenylprop-2-en-1-yl)piperazin-1-yl]methyl}phenol, Benzophenone, and Cinnamaldehyde.

1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine

Pharmaceuticals